We examined the immunogcnicity and rcactigeni- city of a recombinant DNA yeast-derived hepatitis B vaccine in healthy adults. Thirty medical professionals who bad been working at the Akdcniz University Hospital were vaccinated with hepatitis B vaccine according to a 0,1, and 6 month vaccination schedule. One month after the third dose, seroconversion rate was 100% and all subjects had antibodies to hepatitis B surface antigen tilers in excess of 10IU / L. No serious adverse reactions attributable to the vaccine, were observed.